Cartalax Doses Used in Published Studies: What Researchers Reported

Answer first: what the published record contains

Searches for a Cartalax dose usually expect a chart: milligrams, frequency, cycle length. The published literature does not support one. The studies most often cited for this peptide family are laboratory experiments — peptides added to cultured human cells, or administered to rodents in disease models — and each paper chose an exposure that suited its own experimental system. None of the verified papers summarised here was a dose-finding trial in humans, and none established a human dosing schedule. This page therefore describes what the studies did, not what anyone should do. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or compound.

What "Cartalax" refers to in the peer-reviewed literature

"Cartalax" is a trade-style name associated with the short peptide AED (alanyl-glutamyl-aspartic acid), one of a family of two-, three- and four-amino-acid peptides investigated in Russian gerontology and cell-biology laboratories. In indexed journals the compound is usually written as the amino-acid sequence rather than the brand name, which is why a literature search for the brand returns far less than a search for the sequence. The broader family includes the dipeptide KE, the tetrapeptide AEDG, and other tripeptides; a 2025 review of the pineal tetrapeptide AEDG summarised how this class of short peptides has been studied as putative regulators of gene expression and cell function (PMID 40141333). Researchers in this field have proposed that short peptides can interact with DNA and modulate transcription, an idea outlined in a 2016 overview of short peptides and gene expression (PMID 27909961).

Because of that naming pattern, anyone assembling a "Cartalax dosing" picture is actually assembling results from several different peptides, several different models and several different laboratories. That heterogeneity is the first reason a single number cannot be extracted from the literature.

Study by study: models, species and what was administered

Human skin fibroblasts in culture

The most directly relevant published work on AED used human skin fibroblasts undergoing replicative ageing in culture: a 2020 comparison examined the effects of the KE and AED peptides on the functional activity of these cells across passages, with the peptides added to the culture system rather than given to an organism (PMID 33231794). An earlier 2016 report in the same experimental tradition described peptide regulation of skin fibroblast functions during in vitro ageing, again as a cell-culture exposure over successive passages (PMID 27259496). In both cases the relevant quantity is a concentration in the culture medium and an exposure measured in passages or days of culture — not a dose to a person. The original methods sections state those concentrations; this page does not reproduce them as a chart, because a medium concentration has no defensible translation into an amount administered to a human being.

Oral stem cells and other primary human cells

A 2020 paper in Stem Cell Reviews and Reports examined whether short peptides could protect oral (gingival) stem cells from ageing in culture, using peptide exposure of the cells themselves as the intervention (PMID 31677028). A 2019 study of the tetrapeptide AEDG applied the peptide to phytohaemagglutinin-stimulated human blood lymphocytes and reported changes in telomere length and mitotic index in that culture system (PMID 31761987). Both are in vitro designs: the peptide reached the cells directly, with no absorption, distribution, metabolism or excretion involved.

Animal models of kidney injury

Animal work in this family has focused on organ-injury models rather than on ageing endpoints. A 2015 study reported that peptides restored aspects of kidney function in rats with cisplatin-induced acute renal failure (PMID 26515176), and a 2017 study described a nephroprotective effect of the EDL peptide in rodent models of acute kidney injury of different origins (PMID 28744634). These are separate peptides from AED and separate endpoints from cartilage or connective tissue, so they inform the general pharmacology of short peptides in animals rather than any Cartalax-specific schedule.

Neurological models

A 2021 paper examined tripeptides described as epigenetic regulators in a mouse model of Alzheimer's disease and reported neuroprotective effects on the measured outcomes in that model (PMID 34071923). A 2021 Russian-language review discussed epigenetic regulation of adaptogenesis in pathology and ageing and placed this peptide class within that framework (PMID 33993656). Neither paper offers a human schedule.

Tissue specificity and biochemical work

An early 2001 report described tissue-specific effects of peptides across different organ cultures, an idea that underpins much of the later work in this family (PMID 11713572). A 2020 biochemistry paper characterised a peptide–protein complex from cattle sclera and its chaperone activity, illustrating that some products in this space are tissue extracts rather than defined synthetic tripeptides (PMID 33294633). That distinction matters: an extract and a synthetic three-amino-acid peptide are not interchangeable, and their published exposures cannot be pooled.

Models reported in the verified literature

Why a culture concentration is not a dose

When researchers add a peptide to a dish of fibroblasts, every cell sits in a known, constant concentration of the compound for the whole exposure. Nothing filters it through a gut, a liver or a kidney; nothing binds it to plasma proteins; nothing clears it. The fibroblast and stem-cell studies in this family all share that design (PMID 33231794, PMID 31677028). A body never reproduces those conditions. There is no arithmetic that turns a concentration in millilitres of medium into milligrams for a 70-kilogram adult, which is why translating culture work into a personal amount is a category error rather than a calculation.

Why animal doses do not convert either

Rodent studies come closer to whole-organism pharmacology, but the animal work in this literature was built around induced pathology — cisplatin nephrotoxicity in rats (PMID 26515176), acute kidney injury of varied origin (PMID 28744634) and a transgenic-style Alzheimer's model (PMID 34071923) — rather than around healthy-subject dose ranging. Animal-to-human scaling requires allometric conversion, species pharmacokinetic data, a defined toxicology package and then staged human trials. For AED specifically, the verified record contains none of those steps, so an amount used in a rat experiment remains an amount used in a rat experiment.

Routes and durations as described

Route in the cell studies was simply addition to the culture medium, and duration was expressed in passages or days of culture rather than weeks of treatment (PMID 27259496). In the animal studies, route and schedule were tied to the injury model — peptides were given over the short window in which cisplatin-induced renal damage develops and is measured (PMID 26515176), a design that says nothing about long-term administration in a healthy organism. Reviews in this area have discussed mechanisms and gene-expression hypotheses rather than posology (PMID 27909961, PMID 40141333).

Adverse Events and Tolerability: What Studies Report

The verified papers are mechanistic rather than safety-focused, and they do not present structured adverse-event reporting of the kind found in registrational clinical trials. Cell-culture studies of AED and related peptides reported effects on cell function and proliferation markers in fibroblasts and stem cells without describing human tolerability outcomes (PMID 33231794, PMID 31677028). Animal studies in kidney and neurological models reported changes in the outcome measures they were designed to capture rather than systematic toxicity panels (PMID 28744634, PMID 34071923). A 2025 review of the closely related tetrapeptide AEDG likewise summarised bioactivity rather than a human safety database (PMID 40141333). Absence of reported harm in small mechanistic experiments is not evidence of safety in people; it reflects what those studies were built to measure.

What would have to exist before dosing statements were possible

• Human pharmacokinetics for AED: absorption, half-life, distribution and clearance, none of which appear in the verified record.
• Formal toxicology across species and exposure durations.
• Dose-ranging trials in humans with pre-registered endpoints, rather than culture experiments in fibroblasts (PMID 27259496) or lymphocytes (PMID 31761987).
• Independent replication outside the small number of laboratories that generated most of this literature (PMID 11713572).

How to read a "dosage" claim you encounter elsewhere

Numbers circulating for this peptide generally come from one of three places: a culture concentration lifted out of an in vitro methods section (PMID 33231794), an animal schedule from an injury model (PMID 26515176), or a product label with no published trial behind it. Checking which of the three a number came from, and whether the peptide in the source was even AED rather than KE, EDL or AEDG (PMID 28744634), usually resolves most of the confusion. Materials in this space are frequently labelled for research use only and are not approved drugs; that regulatory status is itself part of why no clinical dosing guidance exists.

References

• Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties (International Journal of Molecular Sciences, 2025)
• Short Peptides Regulate Gene Expression (Bulletin of Experimental Biology and Medicine, 2016)
• Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes (Bulletin of Experimental Biology and Medicine, 2019)
• Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure (Bulletin of Experimental Biology and Medicine, 2015)
• Short Peptides Protect Oral Stem Cells from Ageing (Stem Cell Reviews and Reports, 2020)
• Peptide-protein complex from cattle sclera: Structural aspects and chaperone activity (Biochemistry and Biophysics Reports, 2020)
• Epigenetic regulation of adaptogenesis by pathology and aging (Advances in Gerontology, 2021)
• Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer's Disease (Pharmaceuticals, 2021)
• Tissue-specific effects of peptides (Bulletin of Experimental Biology and Medicine, 2001)
• Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro (Bulletin of Experimental Biology and Medicine, 2016)
• Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis (Bulletin of Experimental Biology and Medicine, 2017)
• Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging (Bulletin of Experimental Biology and Medicine, 2020)